Evidence map›Paper›PMID 42865121›Full record

Observational studyNephrology (Carlton, Vic.)2026

Cancer Risk in Haemodialysis Patients Compared With That in the General Population: A Multicenter Questionnaire-Based Study in Okinawa, Japan.

Yoko Arakawa, Yuriko Ishida, Akira Higa, Takeshi Tana, Takuhiro Moromizato, Kentaro Kohagura, Kunitoshi Iseki

Abstract readComparative StudyMulticenter StudyObservational Study
In one paragraph

Observational study in Nephrology (Carlton, Vic.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoko ArakawaShuri Jokamachi Clinic Daiichi, Naha, Okinawa, Japan.ORCID https://orcid.org/0009-0008-2491-8584
Yuriko IshidaShuri Jokamachi Clinic Daini, Naha, Okinawa, Japan.
Akira HigaShuri Jokamachi Clinic Daini, Naha, Okinawa, Japan.
Takeshi TanaShuri Jokamachi Clinic Daiichi, Naha, Okinawa, Japan.
Takuhiro MoromizatoNanbu Medical Center and Children's Medical Center, Haebaru-cho, Okinawa, Japan.ORCID https://orcid.org/0000-0002-4546-6918
Kentaro KohaguraDialysis Unit, University of the Ryukyus Hospital, Ginowan, Okinawa, Japan.ORCID https://orcid.org/0000-0003-1636-7889
Kunitoshi IsekiOkinawa Heart and Renal Association (OHRA), Naha, Okinawa, Japan.ORCID https://orcid.org/0000-0001-6624-0216

Funding

Japanese Society for Dialysis Therapy
6 · The paper itself

Abstract

aimDialysis patients face a heightened risk of cancer, particularly kidney cancer. The global aging of dialysis patients suggests that managing cancer may become a critical factor in future healthcare. Given that the chronic uremic state is a cancer risk factor, dialysis patients may face an elevated risk for all cancers. However, the epidemiology of nonkidney cancers, such as colorectal cancer, remains to be fully elucidated.

methodsThis was a retrospective cohort study targeting 74 dialysis facilities in Okinawa Prefecture, Japan. The subjects were patients who received dialysis for a minimum of 90 days between 2015 and 2019 and were diagnosed with cancer after initiating dialysis during this period. The cancer incidence ratio for the study population (21 655 person-years) was then compared with that of the general Okinawan population using standardized incidence ratios.

resultsA total of 404 cancer cases were collected from 56 facilities (76%). The standardized incidence ratios for all cancers was 1.36, with the risk of kidney cancer increasing with longer dialysis vintage. Patients with a dialysis vintage of less than 2 years showed an increased risk of colorectal and lung cancer. The risk of breast cancer was similar to that of the general population.

conclusionThe present study revealed that not all cancer risks were increased among patients receiving haemodialysis. Screening for colorectal and lung cancer in the first 2 years after commencement of dialysis may be important. Further research is needed to determine the efficacy of this approach for patients receiving dialysis.

Indexed as

NeoplasmsRenal DialysisAdultAgedAged, 80 and overFemaleHumansIncidenceJapanMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsSurveys and Questionnairescancerdialysisquestionnairestandardized incidence ratios (SIRs)survey

Identifiers

PMID42865121
PMCPMC13659246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.